<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509065</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001260</org_study_id>
    <nct_id>NCT02509065</nct_id>
  </id_info>
  <brief_title>The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance</brief_title>
  <official_title>The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to determine the effect on mean glucose, hypoglycemia, glucagon
      usage, and insulin usage of adjusting upward the glucose target of the bi-hormonal bionic
      pancreas, and determine whether there is a target at which adequate glycemic control is
      achieved by an insulin-only bionic pancreas with minimal hypoglycemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have two specific aims:

      Aim 1 is to conduct an outpatient study testing multiple configurations of the bionic
      pancreas in 24 adult subjects with type 1 diabetes in a random cross-over study versus usual
      care with an insulin pump. These bionic pancreas configurations include the insulin only BP
      at 145 mg/dl set point, 130 mg/dl set point, 120 mg/dl set point and 110 mg/dl set point and
      the bihormonal BP at 130 mg/dl set point, 115 mg/dl set point and 110 mg/dl set point. These
      arms are all compared to usual care.

      Aim 2 is to evaluate the incremental utility of glucagon in the context of automated insulin
      delivery by the bionic pancreas in preventing hypoglycemia during exercise in the fasted
      state. The 130 mg/dl set points and 110 mg/dl set points also participate in this fasted
      exercise visit. These two set points are double blinded, so neither the subjects nor the
      study staff are aware which arm is bihormonal and which arm is insulin only.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Some of the study arms are double blinded: the 110 mg/dl and 130 mg/dl set point configurations of the bionic pancreas are double blinded, so neither the patient nor the study team know if they are using the bihormonal bionic pancreas or insulin only bionic pancreas</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Continuous Glucose Monitor (CGM) Glucose Values</measure>
    <time_frame>Days 2 and 3</time_frame>
    <description>Glucose values were collected from the Dexcom G4 CGM device every 5 minutes and an average (calculated mean with associated standard deviation) CGM glucose level (mg/dl) was calculated from days 2 and 3 of the study arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Time With CGM &lt; 60 mg/dl</measure>
    <time_frame>Days 2 and 3</time_frame>
    <description>For this calculation we analyzed data from every 5 minutes of CGM data for days 2 and 3 of each study arm. We looked specifically at the percentage time of those roughly 48 hours that had any glucose values less than 60 mg/dl. The final value presented is the percent of time per 2 days of the study arm spent in a specific hypoglycemia range of less than 60 mg/dl with an associated standard deviation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Discordant for Reaching a BG &lt; 60 mg/dl for &gt; 2 Consecutive Plasma Glucose Measurements During Inpatient Exercise Visit</measure>
    <time_frame>Day 4 in-clinic Exercise Visit (110 and 130 mg/dl arms only)</time_frame>
    <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean CGM Glucose</measure>
    <time_frame>Days 1 through 3</time_frame>
    <description>Average glucose according to continuous glucose monitor readings including the 1 day washout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea Severity</measure>
    <time_frame>Days 1-3</time_frame>
    <description>The average severity of nausea, as recorded on a 10 centimeter visual analog scale by the daily e-mail survey they receive. Scores were determined by how many centimeters the subject marked as a surrogate for their nausea level on a daily basis. Any value more than 0 cm indicates some degree of nausea with a score of 10 cm being the worst nausea imaginable. A score less than 3 cm indicates a mild level of nausea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent in: &lt; 50 mg/dl, &lt; 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, &gt; 180 mg/dl, &gt;250 mg/dl</measure>
    <time_frame>Days 2-3</time_frame>
    <description>The fraction of time spent in each of these ranges according to continuous glucose monitor readings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Mean CGM &lt; 154 mg/dl</measure>
    <time_frame>Days 2-3</time_frame>
    <description>The percentage of subjects who's mean CGM glucose level is &lt; 154 mg/dl, which is an estimated hemoglobin a1c &lt; 7%, which is the ADA goal for therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Between the Glucose Curve and 60 mg/dl Calculated From BG Measurements</measure>
    <time_frame>Day 4 in-clinic Exercise Visit (110 and 130 mg/dl arms only)</time_frame>
    <description>Plasma glucose values to create this curve included time points from time 0 to a maximum of 360 minutes, with a sampling frequency of at least every 10 minutes throughout.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Between the Glucose Curve and 60 mg/dl Calculated From CGM Measurements</measure>
    <time_frame>Day 4 in-clinic Exercise Visit (type 1 diabetes only, 110 and 130 mg/dl arms only)</time_frame>
    <description>CGM glucose values to create this curve included time points from time 0 to a maximum of 360 minutes, with a sampling frequency of every 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Start of Exercise to First BG Measurement &lt; 60 mg/dl</measure>
    <time_frame>Day 4 in-clinic Exercise Visit (type 1 diabetes only, 110 and 130 mg/dl arms only)</time_frame>
    <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Start of Exercise to First CGM Measurement &lt; 60 mg/dl</measure>
    <time_frame>Day 4 in-clinic Exercise Visit (110 and 130 mg/dl arms only)</time_frame>
    <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grams of Carbohydrates Given to the Subject to Treat Hypoglycemia</measure>
    <time_frame>Day 4 in-clinic Exercise Visit (110 and 130 mg/dl arms only)</time_frame>
    <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Glucagon Dosing by the Bihormonal Bionic Pancreas From the Start of Exercise Until the End of the Visit</measure>
    <time_frame>Day 4 in-clinic Exercise Visit (110 and 130 mg/dl arms only)</time_frame>
    <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>145 mg/dl Set Point - insulin only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>130 mg/dl Set Point - insulin only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>130 mg/dl Set Point - bihormonal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>115 mg/dl Set Point - bihormonal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg/dl Set Point - bihormonal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>110 mg/dl Set Point - insulin only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>110 mg/dl Set Point - bihormonal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg/dl Set Point - insulin only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bionic Pancreas</intervention_name>
    <description>Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.</description>
    <arm_group_label>100 mg/dl Set Point - bihormonal</arm_group_label>
    <arm_group_label>110 mg/dl Set Point - bihormonal</arm_group_label>
    <arm_group_label>110 mg/dl Set Point - insulin only</arm_group_label>
    <arm_group_label>115 mg/dl Set Point - bihormonal</arm_group_label>
    <arm_group_label>120 mg/dl Set Point - insulin only</arm_group_label>
    <arm_group_label>130 mg/dl Set Point - bihormonal</arm_group_label>
    <arm_group_label>130 mg/dl Set Point - insulin only</arm_group_label>
    <arm_group_label>145 mg/dl Set Point - insulin only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 1 Diabetes Subjects: Age ≥ 18 years and have had clinical type 1 diabetes for at least
        one year, and managed using an insulin pump for ≥ 6 months Type 2 Diabetes subjects: Age ≥
        18 years and have type 2 diabetes managed with rapid acting insulin in an insulin pump, or
        multiple daily injections including both long acting and short acting insulin

          -  Prescription medication regimen stable for &gt; 1 month (except for medications that will
             not affect the safety of the study and are not expected to affect any outcome of the
             study, in the judgment of the principal investigator)

          -  Live within a 60 minute drive-time radius of the central monitoring location

          -  Willing to remain within a 120 minute drive-time radius of the central monitoring
             location throughout the study

          -  Have someone over 18 years of age who lives with them, has access to where they sleep,
             is willing to be in the house when the subject is sleeping, and is willing to receive
             calls from the study staff and check the welfare of the study subject if telemetry
             shows a technical problem or severe biochemical hypoglycemia without subject response
             and the subject does not answer their telephone (up to two individuals can share this
             role, but they must be willing to carefully coordinate with each other and the subject
             so that one of them is clearly designated as having this responsibility at any given
             time)

          -  Willing to wear two infusion sets and one CGM sensor and change sets frequently (at
             least one new glucagon infusion set daily during bi-hormonal arms, and insulin
             infusion set every other day throughout the study)

          -  Have a mobile phone they are willing to keep with them and answer calls from study
             staff

        Exclusion Criteria:

          -  Unable to provide informed consent (e.g. impaired cognition or judgment)

          -  Unable to safely comply with study procedures and reporting requirements (e.g.
             impairment of vision or dexterity that prevents safe operation of the bionic pancreas,
             impaired memory, unable to speak and read English)

          -  Current participation in another diabetes-related clinical trial that, in the judgment
             of the principal investigator, will compromise the results of this study or the safety
             of the subject

          -  Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the
             immediate future, or sexually active without use of contraception

          -  Need to go outside of the designated geographic boundaries during the study

          -  Current alcohol abuse (intake averaging &gt; 3 drinks daily in last 30 days), use of
             marijuana within 1 month of enrollment, or other substance abuse (use within the last
             6 months of controlled substances other than marijuana without a prescription)

          -  Unwilling or unable to refrain from drinking more than 2 drinks in an hour or more
             than 4 drinks in a day or use of marijuana during the trial

          -  Unwilling or unable or to avoid use of drugs that may dull the sensorium, reduce
             sensitivity to symptoms of hypoglycemia, or hinder decision making during the period
             of participation in the study (use of beta blockers will be allowed as long as the
             dose is stable and the subject does not meet the criteria for hypoglycemia unawareness
             while taking that stable dose, but use of benzodiazepines or narcotics, even if by
             prescription, may be excluded according to the judgment of the principal investigator)

          -  History of liver disease that is expected to interfere with the anti-hypoglycemia
             action of glucagon (e.g. liver failure or cirrhosis). Other liver disease (i.e. active
             hepatitis, steatosis, active biliary disease, any tumor of the liver, hemochromatosis,
             glycogen storage disease) may exclude the subject if it causes significant compromise
             to liver function or may do so in an unpredictable fashion.

          -  Renal failure on dialysis

          -  Personal history of cystic fibrosis, pancreatitis, pancreatic tumor, or any other
             pancreatic disease besides type 1 diabetes

          -  Any known history of coronary artery disease including, but not limited to, history of
             myocardial infarction, stress test showing ischemia, history of angina, or history of
             intervention such as coronary artery bypass grafting, percutaneous coronary
             intervention, or enzymatic lysis of a presumed coronary occlusion)

          -  Abnormal EKG consistent with coronary artery disease or increased risk of malignant
             arrhythmia including, but not limited to, evidence of active ischemia, prior
             myocardial infarction, proximal LAD critical stenosis (Wellen's sign), prolonged QT
             interval (&gt; 440 ms). Non-specific ST segment and T wave changes are not grounds for
             exclusion in the absence of symptoms or history of heart disease. A reassuring
             evaluation by a cardiologist after an abnormal EKG finding may allow participation.

          -  Congestive heart failure (established history of CHF, lower extremity edema,
             paroxysmal nocturnal dyspnea, or orthopnea)

          -  History of TIA or stroke

          -  Seizure disorder, history of any non-hypoglycemic seizure within the last two years,
             or ongoing treatment with anticonvulsants

          -  History of hypoglycemic seizures (grand-mal) or coma in the last year

          -  History of pheochromocytoma: fractionated metanephrines will be tested in patients
             with history increasing the risk for a catecholamine secreting tumor:

        oEpisodic or treatment refractory (requiring 4 or more medications to achieve normotension)
        hypertension oParoxysms of tachycardia, pallor, or headache oPersonal or family history of
        MEN 2A, MEN 2B, neurofibromatosis, or von Hippel-Lindau disease

          -  History of adrenal disease or tumor

          -  Hypertension with systolic BP ≥160 mm Hg or diastolic BP ≥100 despite treatment

          -  Untreated or inadequately treated mental illness (indicators would include symptoms
             such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the
             last year), or treatment with anti-psychotic medications that are known to affect
             glucose regulation.

          -  Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be
             susceptible to RF interference

          -  Unable to completely avoid acetaminophen for duration of study

          -  History of adverse reaction to glucagon (including allergy) besides nausea and
             vomiting

          -  Established history of allergy or severe reaction to adhesive or tape that must be
             used in the study

          -  History of eating disorder within the last 2 years, such as anorexia, bulimia, or
             diabulemia or omission of insulin to manipulate weight

          -  History of intentional, inappropriate administration of insulin leading to severe
             hypoglycemia requiring treatment

          -  Type 1 diabetes subjects: Use of oral (e.g. thiazolidinediones, biguanides,
             sulfonylureas, glitinides, DPP-4 inhibitors, SGLT-2 inhibitors) anti-diabetic
             medications

          -  Type 2 diabetes subjects: Use of oral anti-diabetic medications other than metformin

          -  Lives in or frequents areas with poor Verizon wireless network coverage (which would
             prevent remote monitoring)

          -  Any factors that, in the opinion of the principal investigator would interfere with
             the safe completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Russell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masscahusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bionicpancreas.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2015</study_first_posted>
  <results_first_submitted>May 5, 2018</results_first_submitted>
  <results_first_submitted_qc>July 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2018</results_first_posted>
  <last_update_submitted>October 19, 2018</last_update_submitted>
  <last_update_submitted_qc>October 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven J. Russell, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>bionic pancreas</keyword>
  <keyword>artificial pancreas</keyword>
  <keyword>insulin</keyword>
  <keyword>glucagon</keyword>
  <keyword>continuous glucose monitor (CGM)</keyword>
  <keyword>insulin pump</keyword>
  <keyword>outpatient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02509065/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>27 subjects were recruited and found eligible. Of the 27, only 24 subjects participated in the trial.</recruitment_details>
      <pre_assignment_details>There were 24 subjects and a total of 9 study arms.The order of the arms was assigned in a psuedo random cross-over design. The 110 and 120 mg/dl arms were added later and were not included in the original randomization. 11 of the same subjects completed all 9 arms. Each arm had 20 subjects total, but these 20 were not the same cohort in each arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>110B, 110IO</title>
          <description>Arms were completed in the following order: 110 mg/dl bihormonal bionic pancreas, 110 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P2">
          <title>110B, 110IO, 120IO</title>
          <description>Arms were completed in the following order:
110 mg/dl bihormonal bionic pancreas 110 mg/dl insulin only bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P3">
          <title>110IO, 110B, 120IO</title>
          <description>Arms were completed in the following order: 110 mg/dl insulin only bionic pancreas, 110 mg/dl bihormonal bionic pancreas, 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P4">
          <title>UC, 115B, 100B, 145IO, 130B, 130IO</title>
          <description>Arms were completed in the following order: usual care, 115 mg/dl bihormonal bionic pancreas, 100 mg/dl bihormonal bionic pancreas, 145 mg/dl insulin only bionic pancreas, 130 mg/dl bihormonal bionic pancreas, 130 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P5">
          <title>145IO, 100B, 130B, 130IO, UC, 115</title>
          <description>Arms were completed in the following order: 145 mg/dl insulin only bionic pancreas, 100 mg/dl bihormonal bionic pancreas, 130 mg/dl bihormonal bionic pancreas, 130 mg/dl insulin only bionic pancreas, usual care, 115 mg/dl bihormonal bionic pancreas</description>
        </group>
        <group group_id="P6">
          <title>UC, 115B, 145IO, 100B, 130IO, 130B</title>
          <description>Arms were completed in the following order: usual care, 115 mg/dl bihormonal bionic pancreas, 145 mg/dl insulin only bionic pancreas, 100 mg/dl bihormonal bionic pancreas, 130 mg/dl insulin only bionic pancreas, 130 mg/dl bihormonal bionic pancreas</description>
        </group>
        <group group_id="P7">
          <title>130B, 130IO, 115B, UC, 100B, 145IO, 120IO</title>
          <description>Arms were completed in the following order: 130 mg/dl bihormonal bionic pancreas, 130 mg/dl insulin only bionic pancreas, 115 mg/dl bihormonal bionic pancreas, usual care, 100 mg/dl bihormonal bionic pancreas, 145 mg/dl insulin only bionic pancreas, 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P8">
          <title>145IO, 100B, UC, 115B, 130IO, 130B, 110B, 110IO</title>
          <description>Arms were completed in the following order: 145 mg/dl insulin only bionic pancreas, 100 mg/dl bihormonal bionic pancreas, usual care, 115 mg/dl bihormonal bionic pancreas, 130 mg/dl insulin only bionic pancreas, 130 mg/dl bihormonal bionic pancreas, 110 mg/dl bihormonal bionic pancreas, 110 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P9">
          <title>UC, 115B, 100B, 145IO, 130IO, 130B, 110IO, 110B</title>
          <description>Arms were completed int he following order: usual care, 115 mg/dl bihormonal bionic pancreas, 100 mg/dl bihormonal bionic pancreas, 145 mg/dl insulin only bionic pancreas, 130 mg/dl insulin only bionic pancreas, 130 mg/dl bihormonal bionic pancreas, 110 mg/dl insulin only bionic pancreas, 110 mg/dl bihormonal bionic pancreas</description>
        </group>
        <group group_id="P10">
          <title>130IO, 130B, UC, 145IO, 115B, 100B, 110B, 110IO</title>
          <description>Arms were completed in the following order: 130 mg/dl insulin only bionic pancreas, 130 mg/dl bihormonal bionic pancreas, usual care, 145 mg/dl insulin only bionic pancreas, 115 mg/dl bihormonal bionic pancreas, 100 mg/dl bihormonal bionic pancreas, 110 mg/dl bihormonal bionic pancreas, 110 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P11">
          <title>130B, 130IO, UC, 145IO, 115B, 100B, 110B, 110IO</title>
          <description>Arms were completed in the following order: 130 mg/dl bihormonal bionic pancreas,130 mg/dl insulin only bionic pancreas, usual care, 145 mg/dl insulin only bionic pancreas, 115 mg/dl bihormonal bionic pancreas, 100 mg/dl bihormonal bionic pancreas, 110 mg/dl insulin only bionic pancreas, 110 mg/dl bihormonal bionic pancreas</description>
        </group>
        <group group_id="P12">
          <title>100B, 145IO, UC, 115B, 130IO, 130B, 110IO, 110B</title>
          <description>Arms were completed in the following order: 100 mg/dl bihormonal bionic pancreas, 145 mg/dl insulin only bionic pancreas, usual care, 115 mg/dl bihormonal bionic pancreas, 130 mg/dl insulin only bionic pancreas, 130 mg/dl bihormonal bionic pancreas, 110 mg/dl insulin only bionic pancreas, 110 mg/dl bihormonal bionic pancreas</description>
        </group>
        <group group_id="P13">
          <title>130IO, 130B, 145IO, 100B, 115B, UC, 110B, 110IO, 120IO</title>
          <description>Arms were completed in the following order:
130 mg/dl insulin only bionic pancreas 130 mg/dl bihormonal bionic pancreas 145 mg/dl insulin only bionic pancreas 100 mg/dl bihormonal bionic pancreas 115 mg/dl bihormonal bionic pancreas Usual Care 110 mg/dl bihormonal bionic pancreas 110 mg/dl insulin only bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P14">
          <title>115B, UC, 130B, 130IO, 145IO, 100B, 110IO, 110B, 120IO</title>
          <description>Arms were completed in the following order:
115 mg/dl bihormonal bionic pancreas Usual Care 130 mg/dl bihormonal bionic pancreas 130 mg/dl insulin only bionic pancreas 145 mg/dl insulin only bionic pancreas 100 mg/dl bihormonal bionic pancreas 110 mg/dl insulin only bionic pancreas 110 mg/dl bihormonal bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P15">
          <title>UC, 145IO, 130B, 130IO, 100B, 115B, 110IO, 110B, 120IO</title>
          <description>Arms were completed in the following order:
Usual Care 145 mg/dl insulin only bionic pancreas 130 mg/dl bihormonal bionic pancreas 130 mg/dl insulin only bionic pancreas 100 mg/dl bihormonal bionic pancreas 115 mg/dl bihormonal bionic pancreas 110 mg/dl insulin only bionic pancreas 110 mg/dl bihormonal bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P16">
          <title>UC, 145IO, 130B, 130IO, 100B, 115B, 110B, 110IO, 120IO</title>
          <description>Arms were completed in the following order:
Usual Care 145 mg/dl insulin only bionic pancreas 130 mg/dl bihormonal bionic pancreas 130 mg/dl insulin only bionic pancreas 100 mg/dl bihormonal bionic pancreas 115 mg/dl bihormonal bionic pancreas 110 mg/dl bihormonal bionic pancreas 110 mg/dl insulin only bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P17">
          <title>145IO, 100B, UC, 115B, 130B, 130IO, 110IO, 110B, 120IO</title>
          <description>Arms were completed in the following order:
145 mg/dl insulin only bionic pancreas 100 mg/dl bihormonal bionic pancreas Usual Care 115 mg/dl bihormonal bionic pancreas 130 mg/dl bihormonal bionic pancreas 130 mg/dl insulin only bionic pancreas 110 mg/dl insulin only bionic pancreas 110 mg/dl bihormonal bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P18">
          <title>115B, UC, 130B, 130IO, 145IO, 100B, 110B, 110IO, 120IO</title>
          <description>Arms were completed in the following order:
115 mg/dl bihormonal bionic pancreas Usual Care 130 mg/dl bihormonal bionic pancreas 130 mg/dl insulin only bionic pancreas 145 mg/dl insulin only bionic pancreas 100 mg/dl bihormonal bionic pancreas 110 mg/dl bihormonal bionic pancreas 110 mg/dl insulin only bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P19">
          <title>130IO, 130B, 145IO, 100B, 115B, UC, 110IO, 110B, 120IO</title>
          <description>Arms were completed in the following order:
130 mg/dl insulin only bionic pancreas 130 mg/dl bihormonal bionic pancreas 145 mg/dl insulin only bionic pancreas 100 mg/dl bihormonal bionic pancreas 115 mg/dl bihormonal bionic pancreas Usual Care 110 mg/dl insulin only bionic pancreas 110 mg/dl bihormonal bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P20">
          <title>100B, 145IO, UC, 115B, 130IO, 130B, 110IO, 110B, 120IO</title>
          <description>Arms were completed in the following order:
100 mg/dl bihormonal bionic pancreas 145 mg/dl insulin only bionic pancreas Usual Care 115 mg/dl bihormonal bionic pancreas 130 mg/dl insulin only bionic pancreas 130 mg/dl bihormonal bionic pancreas 110 mg/dl insulin only bionic pancreas 110 mg/dl bihormonal bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P21">
          <title>UC, 115B, 145IO, 100B, 130B, 130IO, 110B, 110IO, 120</title>
          <description>Arms were completed in the following order:
Usual Care 115 mg/dl bihormonal bionic pancreas 145 mg/dl insulin only bionic pancreas 100 mg/dl bihormonal bionic pancreas 130 mg/dl bihormonal bionic pancreas 130 mg/dl insulin only bionic pancreas 110 mg/dl bihormonal bionic pancreas 110 mg/dl insulin only bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P22">
          <title>145IO, 100B, 130B, 130IO, UC, 115B, 110IO, 110B, 120IO</title>
          <description>Arms were completed in the following order:
145 mg/dl insulin only bionic pancreas 100 mg/dl bihormonal bionic pancreas 130 mg/dl bihormonal bionic pancreas 130 mg/dl insulin only bionic pancreas Usual Care 115 mg/dl bihormonal bionic pancreas 110 mg/dl insulin only bionic pancreas 110 mg/dl bihormonal bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
        <group group_id="P23">
          <title>130IO, 130B, 115B, UC, 100B, 145IO, 110B, 110IO, 120IO</title>
          <description>Arms were completed in the following order:
130 mg/dl insulin only bionic pancreas 130 mg/dl bihormonal bionic pancreas 115 mg/dl bihormonal bionic pancreas Usual Care 100 mg/dl bihormonal bionic pancreas 145 mg/dl insulin only bionic pancreas 110 mg/dl bihormonal bionic pancreas 110 mg/dl insulin only bionic pancreas 120 mg/dl insulin only bionic pancreas</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="1"/>
                <participants group_id="P21" count="1"/>
                <participants group_id="P22" count="1"/>
                <participants group_id="P23" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="1"/>
                <participants group_id="P21" count="1"/>
                <participants group_id="P22" count="1"/>
                <participants group_id="P23" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>27 subjects were recruited and found eligible but 3 subjects chose not to participate in the study after eligibility determination</population>
      <group_list>
        <group group_id="B1">
          <title>All Enrolled Subjects</title>
          <description>All subjects enrolled into the study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Continuous Glucose Monitor (CGM) Glucose Values</title>
        <description>Glucose values were collected from the Dexcom G4 CGM device every 5 minutes and an average (calculated mean with associated standard deviation) CGM glucose level (mg/dl) was calculated from days 2 and 3 of the study arm.</description>
        <time_frame>Days 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.</description>
          </group>
          <group group_id="O2">
            <title>145 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.</description>
          </group>
          <group group_id="O3">
            <title>130 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>130 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O5">
            <title>115 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O6">
            <title>100 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O7">
            <title>110 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O8">
            <title>110 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O9">
            <title>120 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Continuous Glucose Monitor (CGM) Glucose Values</title>
          <description>Glucose values were collected from the Dexcom G4 CGM device every 5 minutes and an average (calculated mean with associated standard deviation) CGM glucose level (mg/dl) was calculated from days 2 and 3 of the study arm.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" spread="31"/>
                    <measurement group_id="O2" value="174" spread="23"/>
                    <measurement group_id="O3" value="161" spread="17"/>
                    <measurement group_id="O4" value="156" spread="12"/>
                    <measurement group_id="O5" value="146" spread="15"/>
                    <measurement group_id="O6" value="136" spread="14"/>
                    <measurement group_id="O7" value="153" spread="15"/>
                    <measurement group_id="O8" value="148" spread="17"/>
                    <measurement group_id="O9" value="156" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Time With CGM &lt; 60 mg/dl</title>
        <description>For this calculation we analyzed data from every 5 minutes of CGM data for days 2 and 3 of each study arm. We looked specifically at the percentage time of those roughly 48 hours that had any glucose values less than 60 mg/dl. The final value presented is the percent of time per 2 days of the study arm spent in a specific hypoglycemia range of less than 60 mg/dl with an associated standard deviation.</description>
        <time_frame>Days 2 and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.</description>
          </group>
          <group group_id="O2">
            <title>145 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.</description>
          </group>
          <group group_id="O3">
            <title>130 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>130 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O5">
            <title>115 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O6">
            <title>100 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O7">
            <title>110 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O8">
            <title>110 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O9">
            <title>120 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time With CGM &lt; 60 mg/dl</title>
          <description>For this calculation we analyzed data from every 5 minutes of CGM data for days 2 and 3 of each study arm. We looked specifically at the percentage time of those roughly 48 hours that had any glucose values less than 60 mg/dl. The final value presented is the percent of time per 2 days of the study arm spent in a specific hypoglycemia range of less than 60 mg/dl with an associated standard deviation.</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="2.6"/>
                    <measurement group_id="O2" value="0.96" spread="1.5"/>
                    <measurement group_id="O3" value="0.79" spread="1.4"/>
                    <measurement group_id="O4" value="0.55" spread="1.0"/>
                    <measurement group_id="O5" value="0.88" spread="1.2"/>
                    <measurement group_id="O6" value="0.76" spread="1.1"/>
                    <measurement group_id="O7" value="1.34" spread="1.3"/>
                    <measurement group_id="O8" value="0.4" spread="0.6"/>
                    <measurement group_id="O9" value="1.05" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Discordant for Reaching a BG &lt; 60 mg/dl for &gt; 2 Consecutive Plasma Glucose Measurements During Inpatient Exercise Visit</title>
        <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
        <time_frame>Day 4 in-clinic Exercise Visit (110 and 130 mg/dl arms only)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>130 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O2">
            <title>130 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O3">
            <title>110 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>110 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Discordant for Reaching a BG &lt; 60 mg/dl for &gt; 2 Consecutive Plasma Glucose Measurements During Inpatient Exercise Visit</title>
          <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean CGM Glucose</title>
        <description>Average glucose according to continuous glucose monitor readings including the 1 day washout</description>
        <time_frame>Days 1 through 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.</description>
          </group>
          <group group_id="O2">
            <title>145 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.</description>
          </group>
          <group group_id="O3">
            <title>130 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>130 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O5">
            <title>115 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O6">
            <title>100 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O7">
            <title>110 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O8">
            <title>110 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O9">
            <title>120 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean CGM Glucose</title>
          <description>Average glucose according to continuous glucose monitor readings including the 1 day washout</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.8" spread="30.4"/>
                    <measurement group_id="O2" value="177.8" spread="19.5"/>
                    <measurement group_id="O3" value="164.1" spread="15.3"/>
                    <measurement group_id="O4" value="159.4" spread="13.4"/>
                    <measurement group_id="O5" value="151.6" spread="16.1"/>
                    <measurement group_id="O6" value="140.7" spread="15.4"/>
                    <measurement group_id="O7" value="158.8" spread="18.4"/>
                    <measurement group_id="O8" value="155.0" spread="19.4"/>
                    <measurement group_id="O9" value="160.2" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea Severity</title>
        <description>The average severity of nausea, as recorded on a 10 centimeter visual analog scale by the daily e-mail survey they receive. Scores were determined by how many centimeters the subject marked as a surrogate for their nausea level on a daily basis. Any value more than 0 cm indicates some degree of nausea with a score of 10 cm being the worst nausea imaginable. A score less than 3 cm indicates a mild level of nausea.</description>
        <time_frame>Days 1-3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.</description>
          </group>
          <group group_id="O2">
            <title>145 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.</description>
          </group>
          <group group_id="O3">
            <title>130 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>130 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O5">
            <title>115 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O6">
            <title>100 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O7">
            <title>110 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O8">
            <title>110 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O9">
            <title>120 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea Severity</title>
          <description>The average severity of nausea, as recorded on a 10 centimeter visual analog scale by the daily e-mail survey they receive. Scores were determined by how many centimeters the subject marked as a surrogate for their nausea level on a daily basis. Any value more than 0 cm indicates some degree of nausea with a score of 10 cm being the worst nausea imaginable. A score less than 3 cm indicates a mild level of nausea.</description>
          <units>scores on a scale 0-10 cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.5"/>
                    <measurement group_id="O2" value="0.5" spread="1.6"/>
                    <measurement group_id="O3" value="0.4" spread="0.6"/>
                    <measurement group_id="O4" value="0.4" spread="0.6"/>
                    <measurement group_id="O5" value="0.8" spread="1.6"/>
                    <measurement group_id="O6" value="1.2" spread="1.8"/>
                    <measurement group_id="O7" value="0.64" spread="1.25"/>
                    <measurement group_id="O8" value="0.80" spread="1.38"/>
                    <measurement group_id="O9" value="0.26" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent in: &lt; 50 mg/dl, &lt; 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, &gt; 180 mg/dl, &gt;250 mg/dl</title>
        <description>The fraction of time spent in each of these ranges according to continuous glucose monitor readings</description>
        <time_frame>Days 2-3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.</description>
          </group>
          <group group_id="O2">
            <title>145 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.</description>
          </group>
          <group group_id="O3">
            <title>130 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>130 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O5">
            <title>115 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O6">
            <title>100 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O7">
            <title>110 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O8">
            <title>110 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O9">
            <title>120 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent in: &lt; 50 mg/dl, &lt; 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, &gt; 180 mg/dl, &gt;250 mg/dl</title>
          <description>The fraction of time spent in each of these ranges according to continuous glucose monitor readings</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 50 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.6"/>
                    <measurement group_id="O2" value="0.5" spread="1.0"/>
                    <measurement group_id="O3" value="0.2" spread="0.8"/>
                    <measurement group_id="O4" value="0.1" spread="0.3"/>
                    <measurement group_id="O5" value="0.2" spread="0.4"/>
                    <measurement group_id="O6" value="0.2" spread="0.7"/>
                    <measurement group_id="O7" value="0.5" spread="0.7"/>
                    <measurement group_id="O8" value="0.1" spread="0.2"/>
                    <measurement group_id="O9" value="0.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 70 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="6.2"/>
                    <measurement group_id="O2" value="2.4" spread="2.2"/>
                    <measurement group_id="O3" value="2.3" spread="2.1"/>
                    <measurement group_id="O4" value="1.3" spread="2.0"/>
                    <measurement group_id="O5" value="2.3" spread="2.3"/>
                    <measurement group_id="O6" value="2.4" spread="2.0"/>
                    <measurement group_id="O7" value="3.6" spread="2.2"/>
                    <measurement group_id="O8" value="1.2" spread="1.3"/>
                    <measurement group_id="O9" value="2.4" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-120 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" spread="18.8"/>
                    <measurement group_id="O2" value="16.9" spread="5.8"/>
                    <measurement group_id="O3" value="21.3" spread="7.4"/>
                    <measurement group_id="O4" value="25.9" spread="10.2"/>
                    <measurement group_id="O5" value="34.3" spread="8.2"/>
                    <measurement group_id="O6" value="45.3" spread="11.1"/>
                    <measurement group_id="O7" value="30.2" spread="7.1"/>
                    <measurement group_id="O8" value="37.5" spread="10.5"/>
                    <measurement group_id="O9" value="25.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-180 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="19.0"/>
                    <measurement group_id="O2" value="57.0" spread="11.2"/>
                    <measurement group_id="O3" value="67.2" spread="13.6"/>
                    <measurement group_id="O4" value="70.8" spread="10.2"/>
                    <measurement group_id="O5" value="76.1" spread="11.0"/>
                    <measurement group_id="O6" value="80.7" spread="8.2"/>
                    <measurement group_id="O7" value="70.4" spread="10.3"/>
                    <measurement group_id="O8" value="76.5" spread="11.2"/>
                    <measurement group_id="O9" value="69.5" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 180 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="21.5"/>
                    <measurement group_id="O2" value="40.6" spread="40.9"/>
                    <measurement group_id="O3" value="30.5" spread="13.1"/>
                    <measurement group_id="O4" value="27.9" spread="9.8"/>
                    <measurement group_id="O5" value="21.6" spread="10.3"/>
                    <measurement group_id="O6" value="16.9" spread="8.5"/>
                    <measurement group_id="O7" value="26.0" spread="10.2"/>
                    <measurement group_id="O8" value="22.2" spread="11.6"/>
                    <measurement group_id="O9" value="28.2" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 250 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="8.4"/>
                    <measurement group_id="O2" value="11.3" spread="12.0"/>
                    <measurement group_id="O3" value="6.6" spread="7.3"/>
                    <measurement group_id="O4" value="5.1" spread="3.8"/>
                    <measurement group_id="O5" value="5.7" spread="6.7"/>
                    <measurement group_id="O6" value="3.4" spread="4.5"/>
                    <measurement group_id="O7" value="7.7" spread="6.2"/>
                    <measurement group_id="O8" value="6.5" spread="7.0"/>
                    <measurement group_id="O9" value="5.6" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Mean CGM &lt; 154 mg/dl</title>
        <description>The percentage of subjects who's mean CGM glucose level is &lt; 154 mg/dl, which is an estimated hemoglobin a1c &lt; 7%, which is the ADA goal for therapy</description>
        <time_frame>Days 2-3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.</description>
          </group>
          <group group_id="O2">
            <title>145 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.</description>
          </group>
          <group group_id="O3">
            <title>130 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>130 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O5">
            <title>115 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O6">
            <title>100 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.</description>
          </group>
          <group group_id="O7">
            <title>110 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O8">
            <title>110 mg/dl Set Point - Bihormonal</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O9">
            <title>120 mg/dl Set Point - Insulin Only</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Mean CGM &lt; 154 mg/dl</title>
          <description>The percentage of subjects who's mean CGM glucose level is &lt; 154 mg/dl, which is an estimated hemoglobin a1c &lt; 7%, which is the ADA goal for therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Between the Glucose Curve and 60 mg/dl Calculated From BG Measurements</title>
        <description>Plasma glucose values to create this curve included time points from time 0 to a maximum of 360 minutes, with a sampling frequency of at least every 10 minutes throughout.</description>
        <time_frame>Day 4 in-clinic Exercise Visit (110 and 130 mg/dl arms only)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>130 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O2">
            <title>130 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O3">
            <title>110 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>110 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Between the Glucose Curve and 60 mg/dl Calculated From BG Measurements</title>
          <description>Plasma glucose values to create this curve included time points from time 0 to a maximum of 360 minutes, with a sampling frequency of at least every 10 minutes throughout.</description>
          <units>min*mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="26.3" spread="78.5"/>
                    <measurement group_id="O4" value="5.15" spread="23.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Between the Glucose Curve and 60 mg/dl Calculated From CGM Measurements</title>
        <description>CGM glucose values to create this curve included time points from time 0 to a maximum of 360 minutes, with a sampling frequency of every 5 minutes</description>
        <time_frame>Day 4 in-clinic Exercise Visit (type 1 diabetes only, 110 and 130 mg/dl arms only)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>130 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O2">
            <title>130 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O3">
            <title>110 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>110 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Between the Glucose Curve and 60 mg/dl Calculated From CGM Measurements</title>
          <description>CGM glucose values to create this curve included time points from time 0 to a maximum of 360 minutes, with a sampling frequency of every 5 minutes</description>
          <units>min*mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="66.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="29.6" spread="91.5"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Start of Exercise to First BG Measurement &lt; 60 mg/dl</title>
        <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
        <time_frame>Day 4 in-clinic Exercise Visit (type 1 diabetes only, 110 and 130 mg/dl arms only)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>130 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O2">
            <title>130 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O3">
            <title>110 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>110 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Start of Exercise to First BG Measurement &lt; 60 mg/dl</title>
          <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">No BG values &lt; 60 were reached during 130 arms</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">No BG values &lt; 60 were reached during 130 arms</measurement>
                    <measurement group_id="O3" value="46.7" spread="59.2"/>
                    <measurement group_id="O4" value="30" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Start of Exercise to First CGM Measurement &lt; 60 mg/dl</title>
        <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
        <time_frame>Day 4 in-clinic Exercise Visit (110 and 130 mg/dl arms only)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>130 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O2">
            <title>130 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O3">
            <title>110 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>110 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Start of Exercise to First CGM Measurement &lt; 60 mg/dl</title>
          <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="0"/>
                    <measurement group_id="O2" value="NA" spread="NA">There were no CGM values &lt; 60 mg/dl in this arm</measurement>
                    <measurement group_id="O3" value="53.3" spread="31.7"/>
                    <measurement group_id="O4" value="NA" spread="NA">There were no CGM values &lt; 60 mg/dl in this arm</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grams of Carbohydrates Given to the Subject to Treat Hypoglycemia</title>
        <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
        <time_frame>Day 4 in-clinic Exercise Visit (110 and 130 mg/dl arms only)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>130 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O2">
            <title>130 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O3">
            <title>110 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>110 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
        </group_list>
        <measure>
          <title>Grams of Carbohydrates Given to the Subject to Treat Hypoglycemia</title>
          <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
          <units>grams of carbohydrates</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="1.77" spread="5.51"/>
                    <measurement group_id="O4" value="0.86" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Glucagon Dosing by the Bihormonal Bionic Pancreas From the Start of Exercise Until the End of the Visit</title>
        <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
        <time_frame>Day 4 in-clinic Exercise Visit (110 and 130 mg/dl arms only)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>130 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O2">
            <title>130 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O3">
            <title>110 mg/dl Insulin Only Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
          <group group_id="O4">
            <title>110 mg/dl Bihormonal Bionic Pancreas</title>
            <description>Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Glucagon Dosing by the Bihormonal Bionic Pancreas From the Start of Exercise Until the End of the Visit</title>
          <description>During both 110 mg/dl and 130 mg/dl arms, subjects will report for a fasted in-clinic exercise visit, with plasma blood glucose measurements obtained at least every 10 minutes</description>
          <units>mcg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                    <measurement group_id="O2" value="1.36" spread="1.06"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.70" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Days 1-3 of each study arm</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Enrolled Subjects</title>
          <description>All subjects enrolled into the study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Courtney A Balliro</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-1242</phone>
      <email>cballiro@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

